2. Бакулин И.Г., Авалуева Е.Б., Сказываева Е.В. с соавт. Карманные рекомендации. Воспалительные заболевания кишечника. Под ред. И.Г. Бакулина. М. – С.-Пб.: Ремедиум. 2018; 80 с.

3. Kaplan G.G., Ng S.C. Understanding, and preventing the global increase of inflammatory bowel disease. Gastroenterology. 2017; 152(2): 313–21. https://dx.doi.org/10.1053/j.gastro.2016.10.020

4. Sartor R.B. Mechanisms of disease: Pathogenesis of Crohn’s disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006; 3(7): 390–407. https://dx.doi.org/10.1038/ncpgasthep0528.

5. Бакулин И.Г., Жигалова Т.Н., Латария Э.Л. с соавт. Опыт внедрения федерального регистра пациентов с воспалительными заболеваниями кишечника в Санкт-Петербурге. Фарматека. 2017; S5: 56–59.

6. Venema Uniken W.T., Voskuil M.D., Dijkstra G. et al. The genetic background of inflammatory bowel disease: From correlation to causality. J Pathol. 2017; 241(2): 146–58. https://dx.doi.org/10.1002/path.4817.

7. Torres J., Mehandru S., Colombel J.F. et al. Crohn’s disease. Lancet. 2017; 389(10080): 1741–55.https://dx.doi.org/10.1016/S0140-6736(16)31711-1.

8. Маев И.В., Шелыгин Ю.А., Скалинская М.И. с соавт. Патоморфоз воспалительных заболеваний кишечника. Вестник Российской академии медицинских наук. 2020. 75(1): 27–35.

9. Vasant D.H., Paine P.A., Black C.J. et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut. 2021; 70(7): 1214–40. https://dx.doi.org/10.1136/gutjnl-2021-324598.

10. Ивашкин В.Т., Шелыгин Ю.А., Абдулганиева Д.И. с соавт. Клинические рекомендации по диагностике и лечению болезни Крона у взрослых (проект). Колопроктология. 2020; 19(2): 8–38.

11. Абдулганиева Д.И., Абдулхаков Р.А., Алексеева О.П. с соавт. Язвенный колит: клинические рекомендации по диагностике и консервативному лечению (адаптированный вариант в схемах и алгоритмах). Под ред. Е.А. Белоусовой, Ю.А. Шелыгина. М.: ООО «Рекламное агентство «Ре Медиа», ООО Типография «Пи Квадрат». 2021; 48 с.

12. Maaser C., Sturm A., Vavricka S.R. et al. ECCO-ESGAR guideline for diagnostic assessment in IBD part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2019; 13(2):144–64. https://dx.doi.org/10.1093/ecco-jcc/jjy113.

13. Скалинская М.И., Сказываева Е.В., Бакулин И.Г. с соавт. Проблема недифференцированных воспалительных заболеваний кишечника: от мировых воззрений до собственного опыта применения искусственных нейронных сетей. Профилактическая и клиническая медицина. 2019; 2: 74–81.

14. Tingbin X., Tenghui Z., Chao D. et al. Ulcerative Colitis Endoscopic Index of Severity (UCEIS) versus Mayo Endoscopic Score (MES) in guiding the need for colectomy in patients with acute severe colitis. Gastroenterol Rep (Oxf). 2018; 6(1): 38–44.https://dx.doi.org/10.1093/gastro/gox016.

15. Daperno M., D’Haens G., Van Assche G. et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc. 2004; 60(4): 505–12. https://dx.doi.org/10.1016/S0016-5107(04)01878-4.

16. Magro F., Gionchetti P., Eliakim R. et al.; European Crohn’s and Colitis Organisation (ECCO). Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017; 11(6): 649–70. https://dx.doi.org/10.1093/ecco-jcc/jjx008.

17. Torres J., Bonovas S., Doherty S.G. et al. ECCO guidelines on therapeutics in Crohn’s disease: Medical treatment. J Crohns Colitis. 2020; 14(1): 4–22. https://dx.doi.org/10.1093/ecco-jcc/jjz180.

18. Ballard B.R., M’Koma A.E. Gastrointestinal endoscopy biopsy derived proteomic patterns predict indeterminate colitis into ulcerative colitis and Crohn’s colitis. World J Gastrointest Endosc. 2015; 7(7): 670–74. https://dx.doi.org/10.4253/wjge.v7.i7.670.

19. Bourgonje A.R., von Martels J.Z.H., Gabriels R.Y. et al. A combined set of four serum inflammatory biomarkers reliably predicts endoscopic disease activity in inflammatory bowel disease. Front Med (Lausanne). 2019; 6: 251.https://dx.doi.org/10.3389/fmed.2019.00251.

20. Shah S.C., Colombel J.F., Sands B.E., Narula N. Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn’s disease. Aliment Pharmacol Ther. 2016; 43(3): 317–33. https://dx.doi.org/10.1111/apt.13475.

21. Florholmen J. Mucosal healing in the era of biologic agents in treatment of inflammatory bowel disease. Scand J Gastroenterol. 2015; 50(1): 43–52. https://dx.doi.org/10.3109/00365521.2014.977943

22. Cholapranee A., Hazlewood G.S., Kaplan G.G. et al. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn’s disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther. 2017; 45(10): 1291–302. https://dx.doi.org/10.1111/apt.14030.

23. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69(3): 89–95. https://dx.doi.org/10.1067/mcp.2001.113989.

24. Chen P., Zhou G., Lin J. et al. Serum biomarkers for inflammatory bowel disease. Front Med (Lausanne). 2020; 7: 123.https://dx.doi.org/10.3389/fmed.2020.00123.

25. Rogler G., Biedermann L. Clinical utility of biomarkers in IBD. Curr Gastroenterol Rep. 2015; 17(7): 26.https://dx.doi.org/10.1007/s11894-015-0449-x.

26. Prideaux L., De Cruz P., Ng S.C., Kamm M.A. Serological antibodies in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2012; 18(7): 1340–55. https://dx.doi.org/10.1002/ibd.21903.

27. Smids C., Horjus TH.C., Groenen M. et al The value of serum antibodies in differentiating inflammatory bowel disease, predicting disease activity and disease course in the newly diagnosed patient. Scand J Gastroenterol. 2017; 52(10): 1104–12.https://dx.doi.org/10.1080/00365521.2017.1344875.

28. Joossens S., Reinisch W., Vermeire S. et al. The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology. 2002; 122(5): 1242–47. https://dx.doi.org/10.1053/gast.2002.32980.

29. Dubinsky M., Braun J. Diagnostic and prognostic microbial biomarkers in inflammatory bowel diseases. Gastroenterology. 2015; 149(5): 1265–74. https://dx.doi.org/10.1053/j.gastro.2015.08.006.

30. Lee W.I., Subramaniam K., Hawkins C.A., Randall K.L. The significance of ANCA positivity in patients with inflammatory bowel disease. Pathology. 2019; 51(6): 634–39. https://dx.doi.org/10.1016/j.pathol.2019.07.002.

31. Schulte-Pelkum J., Radice A., Norman G.L. et al. Novel clinical and diagnostic aspects of antineutrophil cytoplasmic antibodies. J Immunol Res. 2014; 2014: 185416. https://dx.doi.org/10.1155/2014/185416.

32. Peeters M., Joossens S., Vermeire S. et al. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol. 2001; 96(3): 730–34.https://dx.doi.org/10.1111/j.1572-0241.2001.03613.x.

33. Ohno H., Hase K. Glycoprotein 2 (GP2): Grabbing the FimH bacteria into M cells for mucosal immunity. Gut Microbes. 2010; 1(6): 407–10. https://dx.doi.org/10.4161/gmic.1.6.14078.

34. Lawrance I.C., Hall A., Leong R. et al. A comparative study of goblet cell and pancreatic exocine autoantibodies combined with ASCA and pANCA in Chinese and Caucasian patients with IBD. Inflamm Bowel Dis. 2005; 11(10): 890–97.https://dx.doi.org/10.1097/01.mib.0000182872.76434.8c.

35. Amre D.K., Lu S.E., Costea F., Seidman E.G. Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn’s disease patients. Am J Gastroenterol. 2006; 101(3): 645–52.https://dx.doi.org/10.1111/j.1572-0241.2006.00468.x.

36. Kuna A.T. Serological markers of inflammatory bowel disease. Biochem Med. 2013; 23(1): 28–42.https://dx.doi.org/10.11613/BM.2013.006.

37. Bossuyt X. Serologic markers in inflammatory bowel disease. Clin Chem. 2006; 52(2): 171–81.https://dx.doi.org/10.1373/clinchem.2005.058560.

38. Dubinsky M.C., Lin Y.C., Dutridge D. et al. Serum immune responses predict rapid disease progression among children with Crohn’s disease: Immune responses predict disease progression. Am J Gastroenterol. 2006; 101(2): 360–67.https://dx.doi.org/10.1111/j.1572-0241.2006.00456.x.

39. Mitsuyama K., Niwa M., Takedatsu H. et al. Antibody markers in the diagnosis of inflammatory bowel disease. World J Gastroenterol. 2016; 22(3): 1304–10. https://dx.doi.org/10.3748/wjg.v22.i3.1304.

40. Kuisma J., Jarvinen H., Kahri A., Farkkila M. Factors associated with disease activity of pouchitis after surgery for ulcerative colitis. Scand J Gastroenterol. 2004; 39(6): 544–48. https://dx.doi.org/10.1080/00365520410004668.

41. Korolkova O.Y., Myers J.N., Pellom S.T. et al. Characterization of serum cytokine profile in predominantly colonic inflammatory bowel disease to delineate ulcerative and Crohn’s colitides. Clin Med Insights Gastroenterol. 2015; 8: 29–44.https://dx.doi.org/10.4137/CGast.S2061.

42. Sands B.E. Biomarkers of inflammation in inflammatory bowel disease. Gastroenterology. 2015; 149(5): 1275–85.e2.https://dx.doi.org/10.1053/j.gastro.2015.07.003.

43. Neurath M.F. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014; 14(5): 329–42. https://dx.doi.org/10.1038/nri3661.

44. Strober W., Fuss I.J. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology. 2011; 140(6): 1756–67. https://dx.doi.org/10.1053/j.gastro.2011.02.016.

45. Кононова С.В., Вахитов Т.Я., Кудрявцев И.В. с соавт. Цитокиновый профиль и иммунологический статус у пациентов с язвенным колитом. Вопросы практической педиатрии. 2021; 16(6): 52–62.

46. Вахитов Т.Я., Кудрявцев И.В., Салль Т.С. с соавт. Субпопуляции Т-хелперов, ключевые цитокины и хемокины в патогенезе воспалительных заболеваний кишечника (часть 2). Вопросы практической педиатрии. 2021; 16(1): 41–51.

47. de Lange K.M., Moutsianas L., Lee J.C. et al. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nat Genet. 2017; 49(2): 256–61. https://dx.doi.org/10.1038/ng.3760.

48. Hong S.N., Joung J.G., Bae J.S. et al. RNA-seq reveals transcriptomic differences in inflamed and noninflamed intestinal mucosa of Crohns disease patients compared with normal mucosa of healthy controls. Inflamm Bowel Dis. 2017; 23(7): 1098–108.https://dx.doi.org/10.1097/MIB.0000000000001066

49. Абашкин В.М., Дмитрук О.Г., Щербин Д.Г. Малые некодирующие РНК: биологическая роль и биомедицинское применение. Весці нацыянальнай акадэміі навук Беларусі. Серыя біялагічных навук. 2018; 63 (2): 232–244.

50. Zacharopoulou E., Gazouli M., Tzouvala M. et al. The contribution of long non-coding RNAs in inflammatory bowel diseases. Dig Liver Dis. 2017; 49(10): 1067–72. https://dx.doi.org/10.1016/j.dld.2017.08.003.

51. Chen T., Xue H., Lin R., Huang Z. MiR-34c and PlncRNA1 mediated the function of intestinal epithelial barrier by regulating tight junction proteins in inflammatory bowel disease. Biochem Biophys Res Commun. 2017; 486(1): 6–13.https://dx.doi.org/10.1016/j.bbrc.2017.01.115.

52. Riaz T., Sollid L.M., Olsen I., de Souza G.A. Quantitative proteomics of gut-derived Th1 and Th1/Th17 clones reveal the presence of CD28+ NKG2D- Th1 cytotoxic CD4+ T cells. Mol Cell Proteomics. 2016; 15(3): 1007–16. https://dx.doi.org/10.1074/mcp.M115.050138

53. Duguet F., Locard-Paulet M., Marcellin M. et al. Proteomic analysis of regulatory T cells reveals the importance of Themis1 in the control of their suppressive function. Mol Cell Proteomics. 2017; 16(8): 1416–32. https://dx.doi.org/10.1074/mcp.M116.062745.

54. Titz B., Gadaleta R.M., Lo Sasso G. et al. Proteomics and lipidomics in inflammatory bowel disease research: from mechanistic insights to biomarker identification. Int J Mol Sci. 2018; 19(9): 2775. https://dx.doi.org/10.3390/ijms19092775.